SELECT PUBLICATIONS

Gandara DR et al. Long-term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504). Proc ASCO 2005;Abstract 7059.

Gandara DR et al. Consolidation docetaxel after concurrent chemoradiotherapy in Stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21(10):2004-10. Abstract

Hussain S et al. Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung. Proc ASCO 2005;Abstract 7080.

Kelly K et al. Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III nonsmall cell lung cancer. Proc ASCO 2005;Abstract 7058.

Lynch TJ et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129- 39. Abstract

Lynch TS et al. Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. Proc ASCO 2005;Abstract 7006.

Shepherd FA et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32. Abstract

Tsao M-S et al. Erlotinib in lung cancer — Molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44. Abstract